Shengyuan Yu, n/a

Director
Chinese PLA General Hospital, Beijing, China

Poster(s):

• (T 22) Rimegepant for the Preventive Treatment of Migraine: A Phase 3, Randomized, Double-blind, Placebo-controlled Study in Adults from China

• (T 32) A phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of zavegepant for the acute treatment of migraine in Asian adults

• (T 46) Efficacy and safety of rimegepant in the acute treatment of migraine among Chinese adults: real-world evidence from a multicenter, prospective, observational study

• (T 47) Efficacy of rimegepant for acute migraine attacks presenting with dizziness or vertigo: a post-hoc analysis of a multicenter, prospective, real-world study

• (T 94) Efficacy and safety of zavegepant for the acute treatment of migraine: pooled analysis of two phase 3 randomized controlled trials